Levi & Korsinsky, LLP announces that a ZSAN class action lawsuit has been commenced on behalf of investors who purchased Zosano Pharma Corporation (ZSAN) securities between February 13, 2017 and September 30, 2020. For more on the Zosano Pharma Class Action please contact us today.

According to the Zosano Pharma lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) the Company’s clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company’s New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company’s lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE ZSAN CLASS ACTION, CLICK HERE

If you suffered a loss in Zosano Pharma you have until December 28, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery does not require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com